

■ Time Table

Day 4, February 21 (Sun)

As of February 12

	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
Track 1		SP2 8:00-10:00 Impact of COVID-19 on Clinical Practice and Research in Oncology			10:50-11:30 Awards Ceremony/Award Lecture of Annals of Oncology		MeS33 12:30-13:20 Treatment in ALK+ NSCLC: What is best treatment sequence?		PS3 14:50-16:50 Presidential Session 3							
Track 2	MoS06 7:00-7:50 IDEA collaboration: Past history, current achievement and future directions Adjuvant Chemotherapy for Colon Cancer ~ Latest Evidence and Future Perspective		SY32 9:00-11:00 Adjuvant Clinical Trials in the Precision Medicine Era					MeS40 13:30-14:20 The arrival of an era in which the combined use of anti-CTLA-4 antibody becomes universal				Closing Remarks				
Track 3		SY30 8:00-10:00 Immunotherapy and Targeted Therapy for Rare Cancers					MeS34 12:30-13:20 Basic Research Review: EGFR-TKI response and interaction mechanism with angiogenesis inhibitor		SY34 14:30-16:00 Identifying and Managing AEs in IO-TKI Combination							
Track 4	MoS07 7:00-7:50 The latest management of hyponatremia (SIADH) in cancer patients			SY33 9:00-10:40 New Perspectives on the Treatment of Thyroid Cancer				MeS41 13:30-14:20 Interprofessional collaborations for patients receiving allo-HSCT, considering SOS				SY37 16:30-17:30 A New Era of Genitourinary Cancer Precision Medicine				
Track 5		SY31 8:00-10:00 Immunoncology: the Role of the Tumor Microenvironment					MeS35 12:30-13:20 Impactful Patient-Centered Team Oncology in the immune checkpoint inhibitor era		JS7 14:30-16:30 JSTAR/JSMO Joint Symposium Establishment of Multidisciplinary Treatment System for Malignant Bone and Soft Tissue Tumors							
Track 6	MoS08 7:00-7:50 Advanced Ovarian Cancer: Where are we moving from current (PARP) revolution?		APJS 9:00-11:00 Asia-Pacific/JSMO Joint Symposium CAR-T and New Generation Therapy in Asia-Pacific					MeS42 13:30-14:20 Tumor Agnostic treatment for NTRK fusion gene positive solid tumor		SY36 15:30-17:10 Back to the Future: Re-learning the Biology of Breast Cancer						
Track 7		O15 8:00-9:30 Breast Cancer			MO26 10:30-11:25 Upper GI Tract (Gastric Cancer)		MeS36 12:30-13:20 What we've learned about IO treatment for NSCLC and future challenges ~Focus on Keytruda~		SY35 14:30-16:30 Health Economic Evaluation in Oncology							
Track 8			JS5 8:30-10:30 JCS/JSMO Joint Symposium Oncology and Cardiology-From a Point to a Line, and to an Area-					MeS43 13:30-14:20 Treatment of Pancreatic Cancer 2021 - Treatment strategy considering 2L -		O17 15:30-17:00 Hematologic Malignancies						
Track 9		MO23 8:30-9:25 Leukemia and Other Hematologic Malignancy			MO27 10:30-11:30 Genitourinary Cancer			MeS44 13:30-14:20 New First Line Treatment for EGFR mutation(+) NSCLC		MO35 16:05-17:05 Lower GI Tract (Colorectal Cancer) 2						
Track 10			JS6 9:00-11:00 JSPM/JSMO Joint Symposium How to Integrate Cutting-edge Cancer Treatment and End-of-life Care?				MeS37 12:30-13:20 Now's the time! Reconsider about late line chemotherapy for mCRC.		MO30 14:25-15:20 NSCLC/ Chemotherapy	MO36 16:10-17:00 SCLC/ Mesothelioma						
Track 11		O16 8:30-10:00 Multidisciplinary Team				Highlight of the Day 11:30-12:30		MeS45 13:30-14:20 What is the goal of treatment for ED-SQLC? ~The benefit of Imfinzi~		MO33 15:20-16:30 COVID-19 and Cancer						
Track 12		MO24 8:30-9:25 Tumor Agnostic Approach/ Clinical Study			MO28 10:30-11:30 Multidisciplinary Team 2			MeS46 13:30-14:20 Future Prospects for Improving Colorectal Cancer Treatment Outcomes and clinical practice		MO34 15:20-16:15 Palliative Care/ Symptom Management						
Track 13		MO25 8:30-9:30 NSCLC/ Immunotherapy			MO29 10:30-11:30 NSCLC/TKI 2		MeS38 12:30-13:20 Predictive biomarkers for eribulin efficacy in metastatic breast cancer focusing on tumor microenvironment.		MO31 14:25-15:25 Pancreatic Cancer	MO38 16:15-17:05 Hepatobiliary Cancer						
Track 14		PAP 8:40-9:30 治験を含む臨床試験の枠組みについて	PAP 9:40-10:30 臨床試験と倫理指針について	PAP 10:40-11:30 ガイドラインにおけるクリニカルケースとエッセンスとは			MeS39 12:30-13:20 Advanced GC treatment Past, Present and Future		MO32 14:25-15:25 Breast Cancer/ Metastatic	MO37 16:10-17:05 TR/Genomic Profiling						
Meeting 1 (Pre-registration Required)					ME16 10:30-11:30 Molecular Targeted Therapy for Soft Tissue Sarcoma				PAP 14:30-15:20 グループディスカッション(1)							
Meeting 2 (Pre-registration Required)										PAP 15:30-16:20 グループディスカッション(2)						
Meeting 3 (Pre-registration Required)						ME18 11:30-12:30 Developing Pooled Patient Data From Clinical Trials: Experiences, Achievements, and Future Challenges										
Meeting 4 (Pre-registration Required)						ME19 11:30-12:30 Future Directions for the Treatment of Head And Neck Cancer										

Explanatory Notes

- SP =Special Session
- AJS =ASCO/JSMO Joint Symposium
- EJS =ESMO/JSMO Joint Symposium
- SJS =SIOG/JSMO Joint Symposium
- APJS =Asia-Pacific/JSMO Joint Symposium
- JS =Joint Symposium
- PSY =Presidential Symposium
- SY =Symposium
- ME =Meet the Experts
- MoS =Morning Seminar
- MeS =Medical Seminar
- ES =Evening Seminar
- PS =Presidential Session
- O =Oral Session
- MO =Mini-Oral Session
- PD =Poster Discussion Session
- Simultaneous Interpretation (E&J)
- Live Streaming Only
- Pre-recorded Video (streaming in the designated time only)